Evidence map›Paper›PMID 21304593›Full record

ArticlePLoS pathogens2011

Early target cells of measles virus after aerosol infection of non-human primates.

Ken Lemon, Rory D de Vries, Annelies W Mesman, Stephen McQuaid, Geert van Amerongen, Selma Yüksel, Martin Ludlow, Linda J Rennick, Thijs Kuiken, Bertus K Rima and 4 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06923631 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Unravelling the Measles Paradox in Children: a Disease Associated With Both Immune Suppression and Immune Activation

TypeobservationalSponsorErasmus Medical CenterRan2026 to 2029Enrolled100ConditionsMEASLES DISEASE
NCT07267585 recruitingnot on this mapstarted 2025, after this paper: background citation

Unravelling the Measles Paradox: a Disease Associated With Both Immune Suppression and Immune Activation

TypeobservationalSponsorErasmus Medical CenterRan2025 to 2028Enrolled300ConditionsMEASLES DISEASE
3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 212 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Measles virus reprograms CD4Frontiers in cell and developmental biology · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Alveolar macrophages are early targets of mumps virus.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Ken LemonCentre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University of Belfast, Belfast, United Kingdom.
Rory D de Vries
Annelies W Mesman
Stephen McQuaid
Geert van Amerongen
Selma Yüksel
Martin Ludlow
Linda J Rennick
Thijs Kuiken
Bertus K Rima
Teunis B H Geijtenbeek
Albert D M E Osterhaus
W Paul Duprex
Rik L de Swart
Erasmus University Rotterdam · NLQueen's University Belfast · GBErasmus MC · NLAcademic Medical Center · NLBelfast Health and Social Care Trust · GB

Funding

Medical Research Council G0801001
6 · The paper itself

Abstract

Measles virus (MV) is highly infectious, and has long been thought to enter the host by infecting epithelial cells of the respiratory tract. However, epithelial cells do not express signaling lymphocyte activation molecule (CD150), which is the high-affinity cellular receptor for wild-type MV strains. We have generated a new recombinant MV strain expressing enhanced green fluorescent protein (EGFP), based on a wild-type genotype B3 virus isolate from Khartoum, Sudan (KS). Cynomolgus macaques were infected with a high dose of rMV(KS)EGFP by aerosol inhalation to ensure that the virus could reach the full range of potential target cells throughout the entire respiratory tract. Animals were euthanized 2, 3, 4 or 5 days post-infection (d.p.i., n = 3 per time point) and infected (EGFP(+)) cells were identified at all four time points, albeit at low levels 2 and 3 d.p.i. At these earliest time points, MV-infected cells were exclusively detected in the lungs by fluorescence microscopy, histopathology and/or virus isolation from broncho-alveolar lavage cells. On 2 d.p.i., EGFP(+) cells were phenotypically typed as large mononuclear cells present in the alveolar lumen or lining the alveolar epithelium. One to two days later, larger clusters of MV-infected cells were detected in bronchus-associated lymphoid tissue (BALT) and in the tracheo-bronchial lymph nodes. From 4 d.p.i. onward, MV-infected cells were detected in peripheral blood and various lymphoid tissues. In spite of the possibility for the aerosolized virus to infect cells and lymphoid tissues of the upper respiratory tract, MV-infected cells were not detected in either the tonsils or the adenoids until after onset of viremia. These data strongly suggest that in our model MV entered the host at the alveolar level by infecting macrophages or dendritic cells, which traffic the virus to BALT or regional lymph nodes, resulting in local amplification and subsequent systemic dissemination by viremia.

Indexed as

Viral TropismAerosolsAnimalsCell MovementDendritic CellsDisease Models, AnimalGreen Fluorescent ProteinsInhalation ExposureLeukocytes, MononuclearLungLymph NodesMacaca fascicularisMacrophages, AlveolarMeasles virusPulmonary AlveoliRecombination, GeneticAerosolsGreen Fluorescent ProteinsViral Fusion Proteins

Identifiers

PMID21304593
PMCPMC3029373
OpenAlexW2099480075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.